For more than seventy years, the enzyme phosphofructokinase was understood as a faithful servant of cellular energy metabolism — a fixed landmark in the biochemistry of life. Researchers at the University of Surrey have now discovered that one of its subunits, Pfk2, quietly performs a second role: binding and unwinding RNA to govern when cells divide. The finding reframes a familiar molecule as a molecular diplomat between energy and growth, and invites the humbling question of how many other long-studied proteins carry secrets we have not yet thought to ask about.
Enzyme long studied for energy production has hidden role in cell division
Cobertura Relacionada
Hundreds of thousands of GCSE students in England, Wales and Northern Ireland receive results on August 20, with guidanc…
Fox News · Aug 20 Erika Kirk urges conservative students to maintain activism after husband's deathErika Kirk, now leading Turning Point USA after her husband Charlie Kirk's assassination in September 2025, urges conser…
News-Medical · Aug 20 Scientists discover hidden physics limiting sweat's cooling power in hot, dry airArizona State University researchers identified an overlooked physical process where opposing air currents near the skin…
The Transmitter · Aug 20 Gene Location in Nucleus Controls Brain Development, Study FindsResearch reveals that gene location within the cell nucleus influences activity during brain development, with genes mov…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
This is a basic science discovery about enzyme function with no direct geopolitical implications; it has no bearing on international relations, power dynamics, or regional conflicts.
Lente Econômica
Discovery of dual function in 70-year-old metabolic enzyme (PFK) with potential applications in cancer treatment and cell cycle regulation could drive biotech innovation and pharmaceutical development.
Long-term potential for improved cancer treatments and cell-cycle-related disease therapies; near-term impact minimal as research is in early stages; could reduce healthcare costs if therapies prove effective.
Potential acceleration of FDA approval pathways for novel cancer therapeutics; increased R&D tax incentives for biotech firms; possible patent framework discussions around enzyme-based therapies; regulatory guidance needed for RNA-targeting drug development.